Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Posted to Twitter RE: NASH Conference

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Dec 03, 2022 12:51pm

210 Views

Post# 35148687

RE:Posted to Twitter RE: NASH Conference

So they will talk about phenotypic characterisation of patients in NASH eligible for clinical trial, but not a word on the level of sortilin expression, which is a phenotypic charaterisation, in their trial in cancer.

archeo753 wrote:

Theratechnologies

@Theratech_

We are pleased to announce that we sponsor #MOSAIC - the 1st Global #NASH Trialist Forum. Marilyn de Chantal will speak and participate in a debate on Monday, Dec 5 at 2:40 PM EST during the "MULTIPLE PHENOTYPIC CHARACTERISATION OF PATIENTS ELIGIBLE FOR NASH TRIALS" session.

9:00 AM · Dec 3, 2022

https://mosaic-nash.tmacademy.org/